[go: up one dir, main page]

PL3573983T3 - N-[4-fluoro-5-[[(2S,4S)-2-metylo-4-[(5-metylo-1,2,4-oksadiazol-3-ilo)metoksy]-1-piperydylo]metylo]tiazol-2-ilo]acetamid jako inhibitor OGA - Google Patents

N-[4-fluoro-5-[[(2S,4S)-2-metylo-4-[(5-metylo-1,2,4-oksadiazol-3-ilo)metoksy]-1-piperydylo]metylo]tiazol-2-ilo]acetamid jako inhibitor OGA

Info

Publication number
PL3573983T3
PL3573983T3 PL18703154T PL18703154T PL3573983T3 PL 3573983 T3 PL3573983 T3 PL 3573983T3 PL 18703154 T PL18703154 T PL 18703154T PL 18703154 T PL18703154 T PL 18703154T PL 3573983 T3 PL3573983 T3 PL 3573983T3
Authority
PL
Poland
Prior art keywords
methyl
oxadiazol
thiazol
piperidyl
acetamide
Prior art date
Application number
PL18703154T
Other languages
English (en)
Inventor
Nicolas Jacques Francois Dreyfus
Peter James LINDSAY-SCOTT
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3573983T3 publication Critical patent/PL3573983T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18703154T 2017-01-27 2018-01-19 N-[4-fluoro-5-[[(2S,4S)-2-metylo-4-[(5-metylo-1,2,4-oksadiazol-3-ilo)metoksy]-1-piperydylo]metylo]tiazol-2-ilo]acetamid jako inhibitor OGA PL3573983T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762451137P 2017-01-27 2017-01-27
PCT/US2018/014331 WO2018140299A1 (en) 2017-01-27 2018-01-19 N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
EP18703154.7A EP3573983B1 (en) 2017-01-27 2018-01-19 N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor

Publications (1)

Publication Number Publication Date
PL3573983T3 true PL3573983T3 (pl) 2021-10-04

Family

ID=61157343

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18703154T PL3573983T3 (pl) 2017-01-27 2018-01-19 N-[4-fluoro-5-[[(2S,4S)-2-metylo-4-[(5-metylo-1,2,4-oksadiazol-3-ilo)metoksy]-1-piperydylo]metylo]tiazol-2-ilo]acetamid jako inhibitor OGA

Country Status (36)

Country Link
US (1) US10081625B2 (pl)
EP (1) EP3573983B1 (pl)
JP (1) JP6738970B2 (pl)
KR (1) KR102275338B1 (pl)
CN (1) CN110198940B (pl)
AR (1) AR110747A1 (pl)
AU (1) AU2018213029B2 (pl)
CA (1) CA3049141C (pl)
CL (1) CL2019001978A1 (pl)
CO (1) CO2019007711A2 (pl)
CR (1) CR20190320A (pl)
CY (1) CY1124257T1 (pl)
DK (1) DK3573983T3 (pl)
DO (1) DOP2019000187A (pl)
EA (1) EA038368B1 (pl)
EC (1) ECSP19053616A (pl)
ES (1) ES2871949T3 (pl)
HR (1) HRP20211011T1 (pl)
HU (1) HUE054990T2 (pl)
IL (1) IL267693B (pl)
JO (1) JOP20190182B1 (pl)
LT (1) LT3573983T (pl)
MA (1) MA47368B1 (pl)
MD (1) MD3573983T2 (pl)
MX (1) MX387166B (pl)
MY (1) MY197494A (pl)
PE (1) PE20191406A1 (pl)
PH (1) PH12019501707A1 (pl)
PL (1) PL3573983T3 (pl)
PT (1) PT3573983T (pl)
RS (1) RS61979B1 (pl)
SI (1) SI3573983T1 (pl)
TW (1) TWI654978B (pl)
UA (1) UA123472C2 (pl)
WO (1) WO2018140299A1 (pl)
ZA (1) ZA201904171B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701315VA (en) 2014-08-28 2017-03-30 Asceneuron Sa Glycosidase inhibitors
EP3419971B1 (en) 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
CN108884078A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
AU2017222962B2 (en) 2016-02-25 2021-03-25 Asceneuron S. A. Acid addition salts of piperazine derivatives
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
TWI669302B (zh) 2017-05-25 2019-08-21 美商美國禮來大藥廠 5-甲基-1,3,4-<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>二唑-2-基化合物
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
TWI726329B (zh) 2018-06-22 2021-05-01 美商美國禮來大藥廠 2,3-二氫呋喃并[2,3-b]吡啶化合物
CN112543648A (zh) * 2018-07-31 2021-03-23 伊莱利利公司 组合疗法
CN112469476B (zh) 2018-07-31 2024-07-16 伊莱利利公司 5-甲基-4-氟-噻唑-2-基化合物
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
MX2021002111A (es) 2018-08-22 2021-07-16 Asceneuron S A Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa.
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
CA3113009A1 (en) 2018-09-19 2020-03-26 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
UY38498A (es) * 2018-12-05 2020-07-31 Biogen Ma Inc Inhibidores de o-glucoproteina-2- acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo , piperazinilo , oxazepanilo y diazepanilo
JP7504898B2 (ja) * 2019-02-04 2024-06-24 バイオジェン・エムエイ・インコーポレイテッド 二環式エーテルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
WO2021094312A1 (en) 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds
WO2021110656A1 (en) 2019-12-02 2021-06-10 Janssen Pharmaceutica Nv Oga inhibitor compounds
US20230058733A1 (en) 2019-12-18 2023-02-23 Janssen Pharmaceutica Nv Oga inhibitor compounds
AU2020409728A1 (en) 2019-12-18 2022-08-11 Janssen Pharmaceutica Nv OGA inhibitor compounds
WO2021123291A1 (en) 2019-12-18 2021-06-24 Janssen Pharmaceutica Nv Oga inhibitor compounds
AR123031A1 (es) * 2020-07-23 2022-10-26 Lilly Co Eli Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo
MX2023001469A (es) 2020-08-03 2023-06-16 Biogen Ma Inc Formas cristalinas de un inhibidor de la o-glucoproteina-2-acetami do-2-desoxi-3-d-glucopiranosidasa.
MX2024004514A (es) 2021-10-22 2024-05-07 Lilly Co Eli Terapia de combinacion con el inhibidor de o-glcnacasa (oga).
IL314657A (en) 2022-02-03 2024-09-01 Lilly Co Eli Regional tau imaging for diagnosing and treating alzheimer's disease
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses
WO2025184490A1 (en) * 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726763D0 (en) 1987-11-16 1987-12-23 Fujisawa Pharmaceutical Co Thiazole compounds
CN1777584A (zh) 2003-04-18 2006-05-24 伊莱利利公司 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
KR20080087833A (ko) * 2005-12-21 2008-10-01 쉐링 코포레이션 히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체
US20100063032A1 (en) * 2007-03-28 2010-03-11 Debenham John S Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
EP2569291B1 (en) 2010-05-11 2016-04-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
HRP20190857T1 (hr) 2013-03-14 2019-07-12 Merck Patent Gmbh Inhibitori glikozidaze
JP6370294B2 (ja) * 2013-05-30 2018-08-08 大日本住友製薬株式会社 環状アミノメチルピリミジン誘導体
SG11201701315VA (en) * 2014-08-28 2017-03-30 Asceneuron Sa Glycosidase inhibitors
DK3389658T3 (da) 2015-12-18 2021-01-11 Merck Sharp & Dohme Glycosidasehæmmere og anvendelser deraf
CA3045957A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds

Also Published As

Publication number Publication date
UA123472C2 (uk) 2021-04-07
MX2019008846A (es) 2019-09-10
ES2871949T3 (es) 2021-11-02
JP6738970B2 (ja) 2020-08-12
CN110198940B (zh) 2022-09-23
IL267693B (en) 2021-08-31
CA3049141A1 (en) 2018-08-02
RS61979B1 (sr) 2021-07-30
CY1124257T1 (el) 2022-07-22
PE20191406A1 (es) 2019-10-04
DOP2019000187A (es) 2019-08-15
EP3573983B1 (en) 2021-04-21
HRP20211011T1 (hr) 2021-09-17
US10081625B2 (en) 2018-09-25
MY197494A (en) 2023-06-19
ECSP19053616A (es) 2019-08-30
JP2020504142A (ja) 2020-02-06
EP3573983A1 (en) 2019-12-04
NZ754849A (en) 2021-10-29
PH12019501707A1 (en) 2020-03-16
KR20190096421A (ko) 2019-08-19
IL267693A (en) 2019-08-29
DK3573983T3 (da) 2021-06-28
TW201836607A (zh) 2018-10-16
WO2018140299A1 (en) 2018-08-02
TWI654978B (zh) 2019-04-01
JOP20190182A1 (ar) 2019-07-25
BR112019013535A2 (pt) 2020-01-07
JOP20190182B1 (ar) 2023-03-28
MD3573983T2 (ro) 2021-10-31
MA47368B1 (fr) 2021-07-29
LT3573983T (lt) 2021-07-26
CA3049141C (en) 2021-02-16
CO2019007711A2 (es) 2019-07-31
HUE054990T2 (hu) 2021-10-28
EA038368B1 (ru) 2021-08-17
CL2019001978A1 (es) 2019-12-13
PT3573983T (pt) 2021-06-17
EA201991515A1 (ru) 2020-01-16
ZA201904171B (en) 2022-01-26
CN110198940A (zh) 2019-09-03
AU2018213029B2 (en) 2020-11-05
KR102275338B1 (ko) 2021-07-12
AU2018213029A1 (en) 2019-07-04
CR20190320A (es) 2019-08-27
AR110747A1 (es) 2019-05-02
MX387166B (es) 2025-03-19
US20180215751A1 (en) 2018-08-02
SI3573983T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
PL3573983T3 (pl) N-[4-fluoro-5-[[(2S,4S)-2-metylo-4-[(5-metylo-1,2,4-oksadiazol-3-ilo)metoksy]-1-piperydylo]metylo]tiazol-2-ilo]acetamid jako inhibitor OGA
NO2022023I1 (no) Ponesimod (IUPAC name: (R)-5-[3-chloro-4-(2,3-dih ydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolylthiazolidin-4-one) and harmaceutically acceptable salts thereof
LT3494115T (lt) N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai
DK4299135T3 (da) Benzisoxazol-sulfonamid-derivater
EP3794492C0 (en) Trusted contextual content
SI3713919T1 (sl) Kristalinične oblike n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil) fenil)kinolin-8-sulfonamida
PL3621960T3 (pl) Tienopirydyny i benzotiofeny użyteczne jako inhibitory irak4
DE112020002266A5 (de) Kühlvorrichtung
HUE054703T2 (hu) N-[5-(amino-szulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamid szabad bázis hemihidrát, annak elõállítási eljárásai és alkalmazásai
EP3471677A4 (en) Sensor for absorbent article
HUE045226T2 (hu) Herbicid hatású N-(1,3,4-oxadiazol-2-il)arilkarboxamid-származékok
EP4011542A4 (en) TREATMENT DEVICE
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
DK4331607T3 (da) Fast farmaceutisk sammensætning indeholdende 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamid
HUE066793T2 (hu) Oxazol vegyület kristály
EP4048158A4 (en) NEEDLE HANDLING DEVICE
EP3967950A4 (en) REFRIGERATION DEVICE
DK3966418T3 (da) Pakkeanordning
EP3643708C0 (en) 2-[4-(METHYLAMINOMETHYL)PHENYL]-5-FLUORO-BENZOFURAN-7-CARBOXAMIDE HYDROCHLORIDE POLYMORPH, ITS PREPARATION PROCESS AND APPLICATION
EP4168384A4 (en) THYROMIMETICS
EP4167986A4 (en) THYROMIMETICS
PL3883733T3 (pl) Urządzenie do obróbki materiału, zwłaszcza tworzywa sztucznego
EP3990064C0 (en) INJECTION DEVICE
EP3952958A4 (en) Injection device
EP3964278A4 (en) Exhaust gas processing device